EARNINGS (LOSS) PER SHARE (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Schedule of earnings per share, basic and diluted

A reconciliation of the numerators and denominators of the basic and diluted loss per share calculations for the three months ended March 31, 2025 and 2024 were as follows:


	Three Months Ended March 31,
	2025			2024
Loss per share (“EPS”):
Basic	$	(0.59	)	$	(0.95	)
Diluted	$	(0.59	)	$	(0.95	)
EPS numerator - basic and diluted:
Net loss	$	(1,756	)	$	(2,898	)
EPS denominator (in thousands):
Weighted average common stock outstanding - basic		2,985			3,041
Common stock equivalents: restricted stock units and restricted shares of common stock (a)		—			—

Weighted average number of common stock outstanding - diluted		2,985			3,041

(a)

The diluted weighted average number of shares of common stock outstanding did not differ from the basic weighted average number of shares of common stock outstanding because the effects of any potential common stock equivalents (see Note 6 to the Condensed Consolidated Financial Statements for further details on unvested restricted stock units) were anti-dilutive and therefore not included in the calculation of the denominator of dilutive earnings per share.

A reconciliation of the numerators and denominators of the basic and diluted (loss) earnings per share calculations were as follows:


	For The Year Ended December 31,
	2024			2023
(Loss) earnings per share (“EPS”):
Basic	$	(1.59	)	$	0.72
Diluted	$	(1.59	)	$	0.70
EPS numerator - basic and diluted:
Net (loss) income	$	(4,770	)	$	2,198
EPS denominator (in thousands):
Weighted average common stock outstanding - basic		3,000			3,064
Common stock equivalents: stock options and restricted stock units		—	(a)		76

Weighted average number of common stock outstanding - diluted		3,000			3,140

(a)

The diluted weighted average number of shares of common stock outstanding did not differ from the basic weighted average number of shares of common stock outstanding because the effects of any potential common stock equivalents (see Note 6 to the Consolidated Financial Statements for further details on unvested restricted stock units) were anti-dilutive and therefore not included in the calculation of the denominator of dilutive earnings per share.

Schedule of antidilutive securities excluded from computation of earnings per share

The weighted average number of shares outstanding used in the computation of diluted net income per share for the years ended December 31, 2024 and 2023 did not include the effect of the following potentially outstanding shares of common stock because the effect would have been anti-dilutive:


	For The Year Ended December 31,
	2024		2023
Unvested restricted stock units		—		247

Total		—		247